Ajanta Pharma Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Consolidate Quarterly Results

Jun'26

Mar'26

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Net Sales

1,625.96

1,421.64

1,374.84

1,353.73

1,302.65

1,170.41

1,146.13

Other Operating Income

0.00

Total Operating income

1,625.96

1,421.64

1,374.84

1,353.73

1,302.65

1,170.41

1,146.13

Raw Material Cost

296.51

256.76

235.07

217.60

207.08

190.96

210.14

Purchase of Finished goods

66.92

71.35

53.55

53.26

51.63

80.18

78.55

(Increase) / Decrease In Stocks

-35.58

-23.30

-2.36

45.95

17.17

12.28

-30.88

Employee Cost

381.11

340.72

330.52

317.01

302.90

279.78

265.17

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

493.42

442.70

375.82

392.08

372.52

310.06

302.32

Total Expenditure (Excl Depreciation)

1,202.38

1,088.23

992.60

1,025.90

951.30

873.26

825.30

Operating Profit (PBDIT) excl Other Income

423.58

333.41

382.24

327.83

351.35

297.15

320.83

Other Income

70.90

61.43

24.97

59.34

26.33

18.11

30.44

Operating Profit (PBDIT)

494.48

394.84

407.21

387.17

377.68

315.26

351.27

Interest

3.18

2.36

5.10

3.39

5.26

6.07

7.91

Exceptional Items

0.00

Gross Profit (PBDT)

491.30

392.48

402.11

383.78

372.42

309.19

343.36

Depreciation

44.50

45.37

43.51

42.97

41.29

39.78

35.97

Profit Before Tax

446.80

347.11

358.60

340.81

331.13

269.41

307.39

Tax

112.58

80.41

84.83

80.62

75.79

44.15

74.51

Provisions and contingencies

0.00

Profit After Tax

334.22

266.70

273.77

260.19

255.34

225.26

232.88

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

334.22

266.70

273.77

260.19

255.34

225.26

232.88

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

334.22

266.70

273.77

260.19

255.34

225.26

232.88

Equity Capital

25.07

Face Value

2.0

Reserves

0.00

Earnings per share (EPS)

26.66

21.28

21.84

20.76

20.37

17.97

18.58

Diluted Earnings per share

26.72

21.34

21.91

20.82

20.43

18.0

18.59

Operating Profit Margin (Excl OI)

26.05%

23.45%

27.8%

24.22%

26.97%

25.39%

27.99%

Gross Profit Margin

30.22%

27.61%

29.25%

28.35%

28.59%

26.42%

29.96%

PAT Margin

20.56%

18.76%

19.91%

19.22%

19.6%

19.25%

20.32%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - YoY

Net Sales

YoY Growth in quarter ended Jun 2026 is 24.82% vs 13.78% in Jun 2025

Consolidate Net Profit

YoY Growth in quarter ended Jun 2026 is 30.89% vs 3.89% in Jun 2025

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Jun 2026 is 20.56% vs 6.36% in Jun 2025

Interest

YoY Growth in quarter ended Jun 2026 is -39.54% vs 620.55% in Jun 2025

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Jun 2026 has fallen from Jun 2025

Compare Quarterly Results Of Ajanta Pharma With

Select Peers

Figures in Cr

Consolidate Quarterly Results

Change(INR)

Change(%)

Net Sales

1,625.96

938.44

687.52

73.26%

Other Operating Income

0.00

Total Operating income

1,625.96

938.44

687.52

73.26%

Raw Material Cost

296.51

72.95

223.56

306.46%

Purchase of Finished goods

66.92

378.62

-311.70

-82.33%

(Increase) / Decrease In Stocks

-35.58

-123.63

88.05

71.22%

Employee Cost

381.11

159.04

222.07

139.63%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

493.42

155.96

337.46

216.38%

Total Expenditure (Excl Depreciation)

1,202.38

642.94

559.44

87.01%

Operating Profit (PBDIT) excl Other Income

423.58

295.50

128.08

43.34%

Other Income

70.90

43.76

27.14

62.02%

Operating Profit (PBDIT)

494.48

339.26

155.22

45.75%

Interest

3.18

0.97

2.21

227.84%

Exceptional Items

0.00

Gross Profit (PBDT)

491.30

338.29

153.01

45.23%

Depreciation

44.50

15.84

28.66

180.93%

Profit Before Tax

446.80

322.45

124.35

38.56%

Tax

112.58

85.27

27.31

32.03%

Provisions and contingencies

0.00

Profit After Tax

334.22

237.18

97.04

40.91%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

334.22

237.18

97.04

40.91%

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

334.22

237.18

97.04

40.91%

Equity Capital

25.07

169.41

-144.34

-85.20%

Face Value

2.00

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

26.66

14.00

12.66

90.43%

Diluted Earnings per share

26.72

14.00

12.72

90.86%

Operating Profit Margin (Excl OI)

26.05%

31.49%

0.00

-5.44%

Gross Profit Margin

30.22%

36.05%

0.00

-5.83%

PAT Margin

20.56%

25.27%

0.00

-4.71%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 1,625.96 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 14.37% vs 3.40% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 24.82% vs 13.78% in Jun 2025

Quarterly - Consolidate Net Profit

Consolidate Net Profit 334.22 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 25.32% vs -2.58% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 30.89% vs 3.89% in Jun 2025

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 423.58 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 27.04% vs -12.77% in Mar 2026

YoY Growth in quarter ended Jun 2026 is 20.56% vs 6.36% in Jun 2025

Quarterly - Interest

Interest 3.18 Cr

in Jun 2026

Figures in Cr

QoQ Growth in quarter ended Jun 2026 is 34.75% vs -53.73% in Mar 2026

YoY Growth in quarter ended Jun 2026 is -39.54% vs 620.55% in Jun 2025

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 26.05%

in Jun 2026

Figures in %

QoQ Growth in quarter ended Jun 2026 has improved from Mar 2026

YoY Growth in quarter ended Jun 2026 has fallen from Jun 2025